About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Daily Archives: April 1, 2010
The Paradigm Shift – From SEO to SMO (Social Media Optimization) – My 2 Euros’ Worth in Berlin and an Interview with Andrew Spong
At the Second Annual ExL European Digital Pharma Conference held at Bayer Headquarters in Berlin this week, I had the privilege of sitting on a panel that was called "The Two Way Relationship Behind Social Media is Rooted in Listening" … Continue reading
Posted in New and Social Media, Social Media
1 Comment
Liberalizing Regulations to Allow the Freer Flow of Information To Patients Globally – A Call for Harmonization
Is a patient in Europe different from a patient in the US? No? Then why are they treated so differently when it comes to information flow? I have spent the past few days in Berlin at the Second Annual … Continue reading
Posted in Uncategorized
2 Comments